Study Summary
The present study evaluates the safety and efficacy of humanized Chimeric antigen receptor T cells (CAR-T) in treating recurrent or refractory B cell malignancy targeting CD19 with a humanized scFv. All participants will receive autologous chimeric antigen receptor engineered T cells.
Want to learn more about this trial?
Request More InfoInterventions
CAR-TBIOLOGICAL
Patients will be infused with autologous CAR-T infusion in a dose escalating manner.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Huaian First People's Hospital | Huai'an | Jiangsu | China |
| Affiliated hospital of Xuzhou medical college | Xuzhou | Jiangsu | China |